Kim Jae-Min, Kim Sung-Wan, Stewart Robert, Kim Seon-Young, Yoon Jin-Sang, Jung Sung-Won, Lee Min-Soo, Yim Hyeon-Woo, Jun Tae-Youn
Department of Psychiatry, Chonnam National University Medical School, Gwangju, Republic of Korea.
Hum Psychopharmacol. 2011 Jan;26(1):41-50. doi: 10.1002/hup.1168.
To estimate the 12-week remission rate of patients with depressive disorders and predictors of this in a naturalistic clinical setting in South Korea.
For people with DSM-IV depressive disorders about to receive treatment at 18 hospitals, data on sociodemographic and health status were obtained. A free choice of clinical interventions was allowed and naturalistic follow-up took place at 1, 2, 4, 8, and 12 weeks later. Remission was defined as a Hamilton Depression Rating Scale score of ≤7 sustained to 12 weeks or last follow-up, if earlier.
For 723 participants, the 12-week remission rate was 31.4%. Remission was more likely in women, and in patients without a prior history of suicide attempt, and those with lower baseline anxiety.
Remission associated with unrestricted clinical interventions was comparable to STAR*D estimates for citalopram alone. Comorbid anxiety and previous suicide attempt were markers of worse outcome.
在韩国的自然临床环境中，评估抑郁症患者的12周缓解率及其预测因素。
对于即将在18家医院接受治疗的DSM-IV抑郁症患者，获取了社会人口统计学和健康状况数据。允许患者自由选择临床干预措施，并在1、2、4、8和12周后进行自然随访。缓解定义为汉密尔顿抑郁量表评分≤7，并持续至12周或更早的最后一次随访。
723名参与者的12周缓解率为31.4%。女性、无前自杀未遂史的患者以及基线焦虑程度较低的患者更有可能实现缓解。
与无限制临床干预相关的缓解率与仅使用西酞普兰的STAR*D研究估计值相当。共病焦虑和既往自杀未遂是预后较差的标志。
